{
  "meta": {
    "timestamp": "2025-01-06T14:19:25.818420",
    "version": "1.0",
    "type": "search_analysis"
  },
  "companies": [
    {
      "company_name": "Mirum Pharmaceuticals Inc.",
      "symbol": "MIRM",
      "analysis": {
        "historical": {
          "risk_score": 50,
          "key_risks": [
            "Regulatory risks due to dependence on FDA and EMA approvals for pipeline products",
            "Market competition in the rare liver disease market",
            "Heavy reliance on the commercial success of Livmarli",
            "Supply chain vulnerabilities from third-party manufacturing",
            "Pricing and reimbursement challenges for rare disease therapies"
          ],
          "controversies": [],
          "environmental_issues": [],
          "social_issues": [
            "Pricing challenges may limit patient access to therapies"
          ],
          "governance_issues": [],
          "recommendation": "caution",
          "confidence_score": 75
        },
        "evidence": {
          "sources": [
            {
              "url": "",
              "title": "Home - Mirum Pharma",
              "snippet": "In Latin, \"mirum\" means remarkable. In science, we develop remarkable therapies for a deserving community. When we discovered that there was an unmet need for people living with rare disease, we got to work. It was imperative to us to identify and develop treatments that had the potential to transform the lives of patients and their families.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. supply chain disruptions",
              "retrieved_at": "2025-01-06T21:19:05.717521+00:00",
              "published_date": null,
              "source_hash": "3c4b8d8cba584444ac6f312b7c1ae3da"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals to Present at the 43rd Annual J.P. Morgan ...",
              "snippet": "FOSTER CITY, Calif., January 06, 2025--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. supply chain disruptions",
              "retrieved_at": "2025-01-06T21:19:05.717667+00:00",
              "published_date": null,
              "source_hash": "e15b164fb247a1eaa16fe25aea3211a0"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals Reports Fourth Quarter and Year-End 2022 ...",
              "snippet": "FOSTER CITY, Calif.--(BUSINESS WIRE)--March 8, 2023--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today reported financial results for the fourth quarter and year-end 2022 and provided a business update. ... conduct and progress of Mirum's ongoing and planned studies for its product candidates and the regulatory approval path for its product ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:18:59.791852+00:00",
              "published_date": null,
              "source_hash": "0944ae90ca45ca846b4a793590044f23"
            },
            {
              "url": "",
              "title": "US FDA approves expanded use of Mirum's liver disease drug",
              "snippet": "The U.S Food and Drug Administration has approved the expanded use of Mirum Pharmaceuticals' oral drug to treat itching caused by a liver disorder in patients aged five years and older, the ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:18:59.791864+00:00",
              "published_date": null,
              "source_hash": "7348d3b5a8e2f0ca594c21063078c593"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals Company Profile 2025: Stock Performance ...",
              "snippet": "Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter \"IBAT) inhibitor (IBATi), is approved for the ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:18:59.791873+00:00",
              "published_date": null,
              "source_hash": "6ba037940383006995e8deb3a2e55269"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals: Strong Buy Recommendation on Promising Interim ...",
              "snippet": "Ed Arce has given his Buy rating due to a combination of factors surrounding Mirum Pharmaceuticals' promising interim study results and potential for regulatory approval. The company's Phase ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:18:59.791883+00:00",
              "published_date": null,
              "source_hash": "c490e377746218545b6b3e2ddd148e79"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals, Inc. SEC 10-Q Report - TradingView",
              "snippet": "Mirum Pharmaceuticals, Inc., a biopharmaceutical company focused on the development and commercialization of innovative therapies for rare liver diseases, has released its Form 10-Q report for the third quarter of 2024. ... Regulatory Approval: Obtaining and maintaining regulatory approval is challenging. The company's product candidates must ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:18:59.791892+00:00",
              "published_date": null,
              "source_hash": "456b20fbac88c2861d97b03fd32985fa"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals Announces Commencement of Public Offering of ...",
              "snippet": "Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare liver diseases. Mirum's approved medication is LIVMARLI\u00ae (maralixibat) oral solution ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:18:59.791902+00:00",
              "published_date": null,
              "source_hash": "e155103a22b070944261f29ecc3247a0"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals to Announce Third Quarter 2024 ... - BioSpace",
              "snippet": "Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. ... Mirum has submitted a new drug application with the FDA for the approval of chenodiol to treat CTX in the U.S. ... Regulatory. 5 Companies That Celebrated First Approvals in 2024. December 23 ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:18:59.791914+00:00",
              "published_date": null,
              "source_hash": "c82b14b019a2dd4f2a77d8356fc19e99"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals Announces FDA Acceptance of New Drug ... - Nasdaq",
              "snippet": "Mirum Pharmaceuticals, Inc. announced today that its New Drug Application for maralixibat, an oral apical sodium dependent bile acid transporter inhibitor for the treatment of cholestatic pruritus ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:18:59.791923+00:00",
              "published_date": null,
              "source_hash": "d1792a9070884598670f4a3541a9946d"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2024 Earnings Call Transcript",
              "snippet": "Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM ... disability and is also characterized by anxiety and language delays. It is an X-linked disorder and males tend to be more severely affected.",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:19:02.237738+00:00",
              "published_date": "2024-11-13T13:37:00+00:00",
              "source_hash": "7eaa2734e7f4f30fa7b08da45a270e32"
            },
            {
              "url": "",
              "title": "Mirum Shares Surge More Than 90% in 6 Months: Here's Why",
              "snippet": "Shares of Mirum Pharmaceuticals, Inc. MIRM have rallied 90.9% in the ... Livmarli sales have been rising steadily since its approval and launch worldwide. Image Source: Zacks Investment Research ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:19:02.237792+00:00",
              "published_date": "2024-11-29T16:53:00+00:00",
              "source_hash": "9ccc6ca00febe0be6ef7142a1dd61166"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
              "snippet": "Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that on December 10, 2024, the Compensation Committee of Mirum's Board of Directors granted inducement awards consisting of non ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. supply chain disruptions",
              "retrieved_at": "2025-01-06T21:19:08.097428+00:00",
              "published_date": "2024-12-10T15:00:00+00:00",
              "source_hash": "5cc3b70d9b499b6ea866777f1d5173cb"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals: Strong Financial Performance and Strategic Growth Justify Buy Rating and Raised Price Target",
              "snippet": "Mirum Pharmaceuticals (MIRM - Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Michael Ulz from Morgan Stanley reiterated a Buy rating ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:19:02.237814+00:00",
              "published_date": "2024-11-13T06:18:00+00:00",
              "source_hash": "14df5e324775c3e5c5d4ba7b461faeb7"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver Meeting",
              "snippet": "FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will present data at the American Association for the Study of Liver Disease's (AASLD ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. regulatory approval delays",
              "retrieved_at": "2025-01-06T21:19:02.237825+00:00",
              "published_date": "2024-11-14T07:59:00+00:00",
              "source_hash": "cc187bde75186f372d7476f39885aa60"
            },
            {
              "url": "",
              "title": "Breaking Down Mirum Pharmaceuticals, Inc. (MIRM) Financial Health: Key ...",
              "snippet": "Is Mirum Pharmaceuticals, Inc. (MIRM) Overvalued or Undervalued?Valuation Analysis When evaluating the financial health of Mirum Pharmaceuticals, Inc. (MIRM), several key metrics can help determine if the company is overvalued or undervalued. ... In 2022, the pharmaceutical industry faced supply chain disruptions leading to a 3.5% increase in ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. supply chain disruptions",
              "retrieved_at": "2025-01-06T21:19:05.717630+00:00",
              "published_date": null,
              "source_hash": "501a7f9963e6e036f2e11d393498bcf8"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals, Inc. - Corporate Responsibility",
              "snippet": "Supply Chain Management. We are committed to ensuring that our supply chain reflects Mirum's values and respect for human rights and the environment. Our relationships with suppliers are based on lawful, efficient, and fair practices and we require suppliers by contract to comply with all applicable laws and regulations.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. supply chain disruptions",
              "retrieved_at": "2025-01-06T21:19:05.717646+00:00",
              "published_date": null,
              "source_hash": "2f42375f3840dbad7be6e8f137681f4b"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals, Inc. - Investor Relations",
              "snippet": "At Mirum Pharma, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the 'unsubscribe' section below. If you experience any issues with this process, please contact us for further assistance.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. supply chain disruptions",
              "retrieved_at": "2025-01-06T21:19:05.717657+00:00",
              "published_date": null,
              "source_hash": "33fcbd878490401b96de0862070dabec"
            },
            {
              "url": "",
              "title": "Leadership Team - Mirum Pharma",
              "snippet": "Here at Mirum, we have brought together some of the top experts in liver disease and pharmaceutical development. It is with passion, insight, and collective experience that we're pushing the boundaries of what is possible. ... Mirum Pharmaceuticals. Mike Grey. Chairman of the Board, Mirum Pharmaceuticals. Saira Ramasastry, MS, MPhil. Managing ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. supply chain disruptions",
              "retrieved_at": "2025-01-06T21:19:05.717677+00:00",
              "published_date": null,
              "source_hash": "4838ab01771769f443ccc81b88d9f9a3"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals, Inc. Information - RocketReach",
              "snippet": "Mirum Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to transforming the treatment of rare diseases affecting children and adults. Mirum has three approved medications: LIVMARLI\u00ae (maralixibat) oral solution, CHOLBAM\u00ae (cholic acid) capsules, and CHENODAL\u00ae (chenodiol) tablets.",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. supply chain disruptions",
              "retrieved_at": "2025-01-06T21:19:05.717686+00:00",
              "published_date": null,
              "source_hash": "45f629dcb0f130420d9b99107cd94c87"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals, Inc. - AnnualReports.com",
              "snippet": "Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company's lead product candidate, maralixibat, is an investigational oral drug in development for Alagille syndrome (ALGS), progressive ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. supply chain disruptions",
              "retrieved_at": "2025-01-06T21:19:05.717699+00:00",
              "published_date": null,
              "source_hash": "48ffd4e90dfb54d9d4c7be4e153e134d"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals, Inc. (MIRM) Company Profile & Overview - Stock ...",
              "snippet": "Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the ...",
              "domain": "",
              "source_type": "web",
              "category": "financial_legal",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. supply chain disruptions",
              "retrieved_at": "2025-01-06T21:19:05.717709+00:00",
              "published_date": null,
              "source_hash": "822e63cd0fe00d408cd9cf3a2b76d5d1"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals, Inc. - Stock Performance",
              "snippet": "At Mirum Pharma, we promise to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the 'unsubscribe' section below. If you experience any issues with this process, please contact us for further assistance.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. pricing controversies",
              "retrieved_at": "2025-01-06T21:19:09.580611+00:00",
              "published_date": null,
              "source_hash": "21f51d62462e9fb102d5720854f08b8b"
            },
            {
              "url": "",
              "title": "Mirum Shares Surge More Than 90% in 6 Months: Here's Why",
              "snippet": "Shares of Mirum Pharmaceuticals, Inc. MIRM have rallied 90.9% in the past six months compared with the industry's increase of just 1.1%. The company's lead product is Livmarli (maralixibat ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. pricing controversies",
              "retrieved_at": "2025-01-06T21:19:12.178010+00:00",
              "published_date": "2024-11-29T16:53:00+00:00",
              "source_hash": "9acc7e7188333ec10e35f61ecad922e9"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2024 Earnings Call Transcript",
              "snippet": "Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Hello everyone, and welcome to the Mirum Pharmaceuticals' Third Quarter 2024 Financial ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. supply chain disruptions",
              "retrieved_at": "2025-01-06T21:19:08.097416+00:00",
              "published_date": "2024-11-13T13:37:00+00:00",
              "source_hash": "8aa989157d18dddbc23b49ee06494e1d"
            },
            {
              "url": "",
              "title": "Why Is Mirum Pharmaceuticals (MIRM) Down 0.7% Since Last Earnings Report?",
              "snippet": "A month has gone by since the last earnings report for Mirum Pharmaceuticals, Inc. (MIRM). Shares have lost about 0.7% in that time frame, underperforming the S&P 500. Will the recent negative ...",
              "domain": "",
              "source_type": "news",
              "category": "financial_legal",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. supply chain disruptions",
              "retrieved_at": "2025-01-06T21:19:08.097438+00:00",
              "published_date": "2024-12-12T11:30:00+00:00",
              "source_hash": "1811576bd6f1d2a44a845f0c121e6ef1"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals to Showcase Data from its LIVMARLI and Volixibat Clinical Programs at AASLD's The Liver Meeting",
              "snippet": "FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will present data at the American Association for the Study of Liver Disease's (AASLD ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. pricing controversies",
              "retrieved_at": "2025-01-06T21:19:12.178111+00:00",
              "published_date": "2024-11-14T13:00:00+00:00",
              "source_hash": "3d0e7a6cb966de1a3fe43cb517e00e66"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals Inc Stock Price Today - Investing.com",
              "snippet": "Mirum Pharmaceuticals Inc Earnings Call Summary for Q4/2024. Q3 net product sales up 89% YoY to $90.3M; full-year revenue guidance raised to $330-$335M",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. pricing controversies",
              "retrieved_at": "2025-01-06T21:19:09.580450+00:00",
              "published_date": null,
              "source_hash": "12e4a5d202675c470e72d44ab3794d15"
            },
            {
              "url": "",
              "title": "MIRM Stock Price | Mirum Pharmaceuticals Inc. Stock Quote (U.S.: Nasdaq ...",
              "snippet": "MIRM | Complete Mirum Pharmaceuticals Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. ... Raymond James cuts Mirum Pharma price target ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. pricing controversies",
              "retrieved_at": "2025-01-06T21:19:09.580556+00:00",
              "published_date": null,
              "source_hash": "712fc9b7b438ffd6793295e5c6c219ce"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals, Inc. (MIRM) - Stock Analysis",
              "snippet": "Get a real-time Mirum Pharmaceuticals, Inc. (MIRM) stock price quote with breaking news, financials, statistics, charts and more. ... the average rating for MIRM stock is \"Strong Buy.\" The 12-month stock price forecast is $57.0, which is an increase of 34.94% from the latest price. Price Target. $57.0 (34.94% upside) Analyst Consensus: Strong ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. pricing controversies",
              "retrieved_at": "2025-01-06T21:19:09.580570+00:00",
              "published_date": null,
              "source_hash": "fd7ba8cd061c1bc78566af9afb24e213"
            },
            {
              "url": "",
              "title": "MIRM: Mirum Pharmaceuticals Inc Stock Price Quote - Bloomberg",
              "snippet": "Stock analysis for Mirum Pharmaceuticals Inc (MIRM:NASDAQ GM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. pricing controversies",
              "retrieved_at": "2025-01-06T21:19:09.580583+00:00",
              "published_date": null,
              "source_hash": "bbe16c56a791ee45712d87fc81f85230"
            },
            {
              "url": "",
              "title": "MIRM - Mirum Pharmaceuticals Stock Price - Barchart.com",
              "snippet": "Mirum Pharmaceuticals Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) today announced that it will report first quarter 2023 financial results on Thursday, May 4, 2023. Mirum will also host a conference call to discuss the first...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. pricing controversies",
              "retrieved_at": "2025-01-06T21:19:09.580591+00:00",
              "published_date": null,
              "source_hash": "04383859daa3227ea9365f922e243118"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals Stock Price - Markets Insider",
              "snippet": "On Friday 12/27/2024 the closing price of the Mirum Pharmaceuticals Inc Registered Shs Reg S Accred Inv share was $41.60 on BTT. Compared to the opening price on Friday 12/27/2024 on BTT of $41.75 ...",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. pricing controversies",
              "retrieved_at": "2025-01-06T21:19:09.580601+00:00",
              "published_date": null,
              "source_hash": "3a248fd3a7384ab6dd641465e4a92c23"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals Company Profile 2025: Stock Performance ...",
              "snippet": "Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. ... As of 31-Dec-2024 the stock price of Mirum Pharmaceuticals is $41.35. What is the current market cap of Mirum Pharmaceuticals?",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. pricing controversies",
              "retrieved_at": "2025-01-06T21:19:09.580620+00:00",
              "published_date": null,
              "source_hash": "efb2f49278fad7b25da171936fe784df"
            },
            {
              "url": "",
              "title": "MIRM | Mirum Pharmaceuticals Inc. Stock Overview (U.S.: Nasdaq ...",
              "snippet": "Complete Mirum Pharmaceuticals Inc. stock information by Barron's. View real-time MIRM stock price and news, along with industry-best analysis.",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. pricing controversies",
              "retrieved_at": "2025-01-06T21:19:09.580629+00:00",
              "published_date": null,
              "source_hash": "8f1c8ff4aae07da65ccd17a3c1d31240"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals | MIRM Stock Price, Company Overview & News - Forbes",
              "snippet": "The company was founded by Niall O'Donnel, Michael Grey and Christopher Peetz in May 2018 and is headquartered in Foster City, CA. Mirum Pharmaceuticals Company Stats As of Invalid DateTime",
              "domain": "",
              "source_type": "web",
              "category": "ethical_social",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. pricing controversies",
              "retrieved_at": "2025-01-06T21:19:09.580637+00:00",
              "published_date": null,
              "source_hash": "8176d30cb96154d4004bff899367892a"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals Inc.",
              "snippet": "Market Capitalization Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. pricing controversies",
              "retrieved_at": "2025-01-06T21:19:12.178089+00:00",
              "published_date": "2024-12-13T00:00:00+00:00",
              "source_hash": "ba19fba178fb8ac692e8d86bab5eea0d"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals: Strong Financial Performance and Strategic Growth Justify Buy Rating and Raised Price Target",
              "snippet": "Mirum Pharmaceuticals ... company, was revisited by a Wall Street analyst yesterday. Analyst Michael Ulz from Morgan Stanley reiterated a Buy rating on the stock and has a $60.00 price target.",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. pricing controversies",
              "retrieved_at": "2025-01-06T21:19:12.178100+00:00",
              "published_date": "2024-11-13T06:18:00+00:00",
              "source_hash": "6f2b3302396ede6fd3d7dbe8c4c5a983"
            },
            {
              "url": "",
              "title": "Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
              "snippet": "December 10, 2024--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM ... Each stock option has an exercise price per share equal to $44.10 per share, Mirum's closing trading price ...",
              "domain": "",
              "source_type": "news",
              "category": "ethical_social",
              "query_context": "Mirum Pharmaceuticals Inc. Mirum Pharmaceuticals Inc. pricing controversies",
              "retrieved_at": "2025-01-06T21:19:12.178120+00:00",
              "published_date": "2024-12-10T00:00:00+00:00",
              "source_hash": "322b6f5a5f5f418e6635bf21fe1675f1"
            }
          ],
          "queries": [
            {
              "category": "financial_legal",
              "query": "Mirum Pharmaceuticals Inc. regulatory approval delays",
              "rationale": "Investigate potential delays or rejections in regulatory approvals for Livmarli or Volixibat",
              "priority": 1
            },
            {
              "category": "financial_legal",
              "query": "Mirum Pharmaceuticals Inc. supply chain disruptions",
              "rationale": "Assess risks related to third-party manufacturing dependencies and supply chain stability",
              "priority": 2
            },
            {
              "category": "ethical_social",
              "query": "Mirum Pharmaceuticals Inc. pricing controversies",
              "rationale": "Examine public or payer concerns regarding the high cost of rare disease therapies like Livmarli",
              "priority": 3
            }
          ]
        },
        "categorization": {
          "product_issues": [],
          "conduct_issues": [],
          "tags": [],
          "patterns": {}
        }
      },
      "metadata": {
        "analysis_timestamp": "2025-01-06T14:19:25.818431",
        "data_confidence": 75,
        "pattern_confidence": null
      }
    }
  ]
}